GlassScriptPhysician profile
Christy Mclaughlin
NPI 1578595120
$8,781.18
in general payments reported to CMS, 2019-2025
31 companies · $2,603 in 2025
The $2,603 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $716 · 2022: $1,314 · 2023: $2,169 · 2024: $1,980 · 2025: $2,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,747 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,746.50 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,412.32 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $782.31 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $631.11 | 2022-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $575.69 | 2022-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $570.44 | 2021-2025 | Austedo, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $546.84 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $513.56 | 2022-2025 | Azstarys |
| Lundbeck LLC | $507.44 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $439.29 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $396.64 | 2021-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $359.35 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $343.15 | 2021-2025 | Trintellix |
| Neos Therapeutics, LP | $318.58 | 2022-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $272.49 | 2022-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $201.28 | 2022-2025 | Ingrezza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $192.32 | 2021-2025 | Xelstrym |
| Tris Pharma INC | $173.93 | 2023-2024 | Dyanavel Xr |
| Bausch Health US, LLC | $116.77 | 2021-2023 | Aplenzin, Wellbutrin |
| Eisai INC. | $64.08 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.32 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $57.05 | 2022-2023 | Quviviq |
| Biogen, INC. | $45.01 | 2024-2025 | Zurzuvae |
| Indivior INC. | $32.23 | 2022 | |
| Braeburn INC. | $30.99 | 2025 | Brixadi |
| Owp Pharmaceuticals, INC. | $23.12 | 2022 | |
| Lilly USA, LLC | $21.86 | 2025 | Zepbound |
| Vertical Pharmaceuticals, LLC | $20.90 | 2025 | Relexxii |
| Almatica Pharma LLC | $20.53 | 2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $18.17 | 2025 | Jornay Pm |
| Harmony Biosciences LLC | $16.21 | 2025 | |
| Sunovion Pharmaceuticals INC. | $15.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.